From the FDA Drug Label
DIRECTIONS Follow dosage below or use as directed by a physician. do not take more than 6 doses in any 24-hour period. age dose adults and children 12 years and over10 to 20 mL (2 to 4 teaspoonfuls) every 4 hours children 6 years to under 12 years5 to 10 mL (1 to 2 teaspoonfuls) every 4 hours children 2 to under 6 years of age2.5 to 5 mL (½ to 1 teaspoonful) every 4 hours children under 2 years of ageconsult a physician
The recommended dose and frequency for Mucinex (Guaifenesin) DM are:
- Adults and children 12 years and over: 10 to 20 mL (2 to 4 teaspoonfuls) every 4 hours
- Children 6 years to under 12 years: 5 to 10 mL (1 to 2 teaspoonfuls) every 4 hours
- Children 2 to under 6 years of age: 2.5 to 5 mL (½ to 1 teaspoonful) every 4 hours
- Children under 2 years of age: consult a physician 1
From the Research
The recommended dose of Mucinex DM (guaifenesin and dextromethorphan) for adults and children 12 years and older is one to two 600mg/30mg extended-release tablets every 12 hours, not exceeding 4 tablets in 24 hours. This dosing recommendation is based on the most recent and highest quality study available, which evaluated the pharmacokinetics and efficacy of extended-release guaifenesin formulations 2.
Key Considerations
- Children under 12 should not take the adult formulation, but age-appropriate children's versions are available with different dosing.
- The medication should be taken with a full glass of water to help loosen mucus, and tablets should be swallowed whole, not crushed or chewed, to maintain the extended-release properties.
- Mucinex DM contains two active ingredients: guaifenesin, which helps thin and loosen mucus in the airways, and dextromethorphan, which suppresses cough.
- The 12-hour dosing interval is designed to provide consistent symptom relief throughout the day.
- If symptoms persist beyond 7 days, worsen, or are accompanied by fever, consult a healthcare provider as this may indicate a more serious condition requiring different treatment.
Supporting Evidence
- A study published in 2013 demonstrated the bioequivalence of extended-release guaifenesin to immediate-release formulations, supporting the use of extended-release formulations for convenience and efficacy 2.
- Another study published in 2017 highlighted the role of guaifenesin in the management of chronic bronchitis and upper respiratory tract infections, emphasizing its safety and efficacy profile 3.
- However, a 2022 study on levofloxacin for tuberculosis treatment in children is not relevant to the dosing of Mucinex DM 4.
- Other studies, such as those published in 2007 and 2015, provide additional context on the mechanisms and effects of guaifenesin, but do not alter the recommended dosing regimen 5, 6.